http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111298140-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-186 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y25-00 |
| filingDate | 2020-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111298140-B |
| titleOfInvention | Reduction-responsive T1/T2 switching MRI contrast agent, preparation method and application thereof |
| abstract | The invention discloses a reduction-responsive T 1 /T 2 switching type MRI contrast agent, a preparation method and application thereof. The contrast agent has the following structural formula: Among them, M is ultra-small iron oxide nanoparticles, X is H or a target molecule, and n is 50-150. The MRI contrast agent provided by the present invention can specifically respond to a higher concentration of glutathione in tumor cells, realize the aggregation of ultra-small iron oxide nanoparticles, and thus realize the switching of T1 contrast agent to T2 contrast agent. It has the advantages of high sensitivity and selectivity, low toxicity and good biocompatibility in tumor diagnosis. |
| priorityDate | 2020-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.